Knight Therapeutics (TSE:GUD) PT Raised to C$5.40

Knight Therapeutics (TSE:GUD) had its target price upped by equities research analysts at Stifel Nicolaus from C$5.25 to C$5.40 in a research note issued to investors on Wednesday, BayStreet.CA reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price target would indicate a potential downside of 5.92% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Royal Bank of Canada boosted their price target on Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Raymond James boosted their price target on Knight Therapeutics from C$7.00 to C$7.50 and gave the company an “outperform” rating in a report on Wednesday, March 6th.

Knight Therapeutics Stock Performance

Shares of Knight Therapeutics stock traded down C$0.03 during trading hours on Wednesday, reaching C$5.74. The company had a trading volume of 7,409 shares, compared to its average volume of 71,256. Knight Therapeutics has a one year low of C$4.35 and a one year high of C$5.95. The business has a fifty day simple moving average of C$5.51 and a 200 day simple moving average of C$5.32. The company has a debt-to-equity ratio of 9.25, a current ratio of 3.20 and a quick ratio of 1.79. The firm has a market cap of C$580.72 million, a PE ratio of -35.88, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.49.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, March 21st. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.05). The business had revenue of C$74.20 million for the quarter, compared to the consensus estimate of C$78.37 million. Knight Therapeutics had a negative net margin of 5.13% and a negative return on equity of 2.14%. On average, analysts anticipate that Knight Therapeutics will post 0.0202158 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Knight Therapeutics news, insider Sime Armoyan sold 10,900 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of C$5.95, for a total transaction of C$64,855.00. Company insiders own 46.45% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.